Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacoinvasive Therapy with Prourokinase for Acute STEMI Registration Study
ChiCTR2100042307Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of University of Science and Technology of China
- Start
- Jan 2021
- Modality
- Metabolic Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of recombinant human prourokinase in myocardial infarction (MI), sponsored by The First Affiliated Hospital of University of Science and Technology of China. Primary endpoint: MACCE adverse clinical events. Started Jan 2021; status: recruiting.
02
Drugs
recombinant human prourokinase
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on ChiCTR2100042307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100042307.